.
MergerLinks Header Logo

Announced

Completed

Sanofi completed the acquisition of Tidal Therapeutics for $310m.

Financials

Edit Data
Transaction Value£225m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Biotechnology

Cross Border

Private

United States

Majority

Completed

pre-clinical stage biotech

Acquisition

Friendly

Synopsis

Edit

Sanofi, a French multinational pharmaceutical company, completed the acquisition of Tidal Therapeutics, a privately owned, pre-clinical stage biotech company, for $310m. "We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population. We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions," Frank Nestle, Sanofi Global Head of Research and Chief Scientific Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US